Immunotherapy combined with chemotherapy improved clinical outcomes over bevacizumab combined with chemotherapy as first‐line therapy in adenocarcinoma patients

PURPOSE: No definite conclusion has yet to be reached for the first‐line treatment combined with chemotherapy for advanced adenocarcinoma NSCLC patients with negative driver genes. This study sought to compare the clinical outcomes of Beva+ChT and IO+ChT as first‐line treatment for this population a...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Min, Li, Ji, Xu, Shuhui, Li, Yuying, Li, Jiatong, Yu, Jinming, Tang, Xiaoyong, Zhu, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028054/
https://www.ncbi.nlm.nih.gov/pubmed/36271595
http://dx.doi.org/10.1002/cam4.5356

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028054/
https://www.ncbi.nlm.nih.gov/pubmed/36271595
http://dx.doi.org/10.1002/cam4.5356

Ejemplares similares